Assess Differences in Pain Following Cryo and Radiofrequency Atrial Fibrillation Ablation
NCT ID: NCT03148392
Last Updated: 2019-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2017-05-16
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation
NCT01803438
CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial
NCT03716934
A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation
NCT00523978
Atrial Fibrillation Registry 2017
NCT05023590
Effect of Catheter Ablation on Left Atrial Function in Persistent Atrial Fibrillation
NCT03443232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based on personal observation, it is felt that patients undergoing Radiofrequency ablation have a higher incidence of chest discomfort and subsequently a greater requirement for pain medications post procedure as compared to those patients undergoing Cryo ablation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cryo Balloon Ablation
Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
No interventions assigned to this group
Radiofrequency Ablation
Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant
* Taking pain medications for acute or chronic conditions at the time of the procedure.
* Undergo a combination of Cryoablation and Radiofrequency ablation
* Radiofrequency group who undergo ablation beyond pulmonary vein isolation
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
Sumit Verma, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sumit Verma, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sumit Verma, MD
Role: PRINCIPAL_INVESTIGATOR
Cardiology Consultants
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Consultants
Pensacola, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Research Manager
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cryo RF Ablation QOL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.